Glucagon-like peptide-1 receptor expression in Xenopus oocytes stimulates inositol trisphosphate-dependent intracellular Ca2+ mobilization  by Gromada, Jesper et al.
Glucagon-like peptide-1 receptor expression in Xenopus oocytes
stimulates inositol trisphosphate-dependent intracellular
Ca2 mobilization
Jesper Gromadaa;*, Charlotte Ankerb, Krister Bokvista, Lotte B. Knudsenb, Philip Wahlb
aDepartment of Islet Cell Physiology, Novo Nordisk A/S, Symbion, Fruebjergvej 3, DK-2100 Copenhagen, Denmark
bDepartment of Molecular Pharmacology, Novo Nordisk A/S, Copenhagen, Denmark
Received 18 February 1998
Abstract The signal transduction pathway of the cloned human
glucagon-like peptide-1 (GLP-1) receptor was studied in voltage-
clamped Xenopus oocytes. Binding of GLP-1(7^36)amide was
associated with cAMP production, increased [Ca2+]i and
activation of Ca2+-dependent Cl3 current. The effect of GLP-
1(7^36)amide reflects intracellular Ca2+ mobilization and was
suppressed by injection of the Ca2+ chelator BAPTA and the
inositol trisphosphate receptor antagonist heparin. The responses
were not mimicked by the adenylate cyclase activator forskolin
and unaffected by the protein kinase A (PKA) inhibitor Rp-
cAMPS. We conclude that GLP-1 receptor expression in
Xenopus oocytes evokes inositol trisphosphate-dependent intra-
cellular Ca2+ mobilization independent of the cAMP/PKA
signaling pathway.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The glucagon-like peptide-1 (GLP-1) receptor belongs to
the glucagon/secretin receptor subfamily of seven-transmem-
brane G protein-coupled receptors [1]. The GLP-1 receptor
couples positively to the adenylate cyclase system and in
some cells stimulates an increase in [Ca2]i. The mechanism
of how GLP-1 promotes a rise in [Ca2]i is not well under-
stood. In one study it was demonstrated that the GLP-1 re-
ceptor following expression in monkey kidney COS cells cou-
ples to both the phospholipase C (PLC) and adenylate cyclase
signaling systems and that the rise in [Ca2]i results from
inositol trisphosphate production [2]. In other cell types,
GLP-1 receptor expression is either not associated with a
rise in the cytoplasmic Ca2 concentration or elevations in
[Ca2]i are secondary to cAMP-dependent activation of pro-
tein kinase A (PKA). For example, stimulation of the re-
combinant GLP-1 receptor in the human-derived cell line
HEK 293 produces a rise in [Ca2]i by promoting Ca2-in-
duced Ca2 release following sensitization of ryanodine recep-
tors by a PKA-dependent mechanism [3]. The pancreatic B-
cell is a target cell for GLP-1. Here, GLP-1 promotes PKA-
dependent Ca2 mobilization from intracellular stores
through Ca2-induced Ca2 release and Ca2-stimulated in-
ositol 1,4,5-trisphosphate (Ins(1,4,5)P3) production [4^6].
Xenopus oocytes are widely used to explore the function of
recombinant ion channels and seven-transmembrane spanning
receptors and are believed to represent a good and convenient
model system. We have used Xenopus oocytes to gain insight
into the cellular mechanism underlying the GLP-1-induced
rise in [Ca2]i. We demonstrate for the ¢rst time that activa-
tion of the cloned human GLP-1 receptor expressed in Xe-
nopus oocytes induces Ins(1,4,5)P3-dependent intracellular
Ca2 mobilization and activation of Ca2-dependent Cl3 cur-
rent which is not mediated by cAMP-induced stimulation of
PKA.
2. Materials and methods
2.1. RNA preparation
The human GLP-1 receptor cDNA was obtained from Dr. B. Tho-
rens (Department of Pharmacology and Toxicology, University of
Lausanne, Switzerland). For preparation of RNA, the GLP-1 receptor
cDNA was linearized and cRNA was synthesized by means of a
cRNA Capping kit (Stratagene, La Jolla, CA, USA). The cRNA
transcript was extracted twice with phenol/chloroform (1:1) and
chloroform/isoamyl alcohol (24:1) and puri¢ed by precipitation with
ammonium acetate and ethanol. cRNA was washed twice with 70%
ethanol, dried, and dissolved in diethyl pyrocarbonate-treated water
(¢nal concentration of cRNA was estimated by agarose gel electro-
phoresis and ethidium bromide staining) and stored at 380‡C.
2.2. Electrophysiology
Mature female Xenopus laevis obtained from Xenopus I (Ann Ar-
bor, MI, USA) and Xenopus Ltd (Redhill, Surrey, UK) were anes-
thetized using 0.15% 3-aminobenzoic acid ethyl ester (MS-222) and 3^
5 ovarian lobes were surgically removed. Oocytes at developmental
stages V^VI were dissected from the ovary and injected with 25 ng (50
nl) cRNA and incubated at 17‡C in Barth’s medium containing (in
mM) 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.3 Ca(NO3)2, 0.4 CaCl2, 0.3
MgSO4 and 15 HEPES (pH 7.4 with NaOH) and supplemented with
0.1 mg/ml gentamicin. Two days after injection the oocytes were
treated with 0.5 mg/ml collagenase for 20^30 min and the follicle
cell layer was removed mechanically with a pair of ¢ne forceps. Re-
cordings of membrane currents were performed under a two-electrode
voltage clamp with a holding potential of 360 mV controlled by a
Turbo TEC O1C ampli¢er (npi electronic GmbH, Tamm, Germany)
using oocytes incubated for 4^7 days following injection. Current and
potential electrodes were ¢lled with 3 M KCl and the pipette resist-
ance was 0.5^1 M6. The zero-current potential was adjusted before
impaling the electrodes into the oocyte. The oocytes were placed in a
small plexiglass chamber and continuously superfused (3 ml/min) with
frog Ringer containing (in mM) 115 NaCl, 2.5 KCl, 1.8 CaCl2 and 10
HEPES (pH 7.2 with NaOH) at room temperature (22‡C). Drugs
were applied through the bath solution and the time required for
the test compound to reach the oocyte was 6 5 s. Intraoocyte injec-
tions were made 30^60 min prior to recordings and injection solutions
FEBS 20015 27-3-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 2 5 4 - 3
*Corresponding author. Fax: (45) 39179762.
E-mail: JLG@novo.dk
Abbreviations: [Ca2]i, intracellular free Ca2 concentration; GLP-1,
glucagon-like peptide-1; GLP-1(7^36)amide, glucagon-like peptide-
1(7^36)amide; Ins(1,4,5)P3, inositol 1,4,5-trisphosphate; PKA, protein
kinase A; PACAP, pituitary adenylate cyclase-activating polypeptide;
PLC, phospholipase C; VIP, vasoactive intestinal peptide
FEBS 20015 FEBS Letters 425 (1998) 277^280
of BAPTA (100 mM), Rp-cAMPS (2 mM), and heparin (4 mg/ml)
were made up in 5 mM HEPES (pH 7.0 KOH). The PKA inhibitor
Rp-cAMPS was obtained from BIOLOG Life Science Institute (Bre-
men, Germany). GLP-1(7^36)amide was synthesized in-house (Novo
Nordisk A/S, Bagsvaerd, Denmark). The correctness of structure and
purity for GLP-1(7^36)amide was estimated by mass, sequence and
HPLC analyses. The GLP-1 receptor antagonist exendin-(9^39) was
from Bachem Feinchemikalien (Bubendorf, Switzerland). Ryanodine
was from Alomone Labs (Jerusalem, Israel). All other chemicals were
purchased from Sigma.
2.3. Measurements of cAMP levels
Intracellular cAMP levels were measured in groups of ¢ve oocytes.
The oocytes were ¢rst incubated in 50 Wl frog Ringer for 30 min in the
presence of 1 mM IBMX and subsequently stimulated with 50 nM
GLP-1(7^36)amide or 10 WM forskolin for 15 min in the continued
presence of IBMX. The reaction was terminated by the addition of
HCl to the incubation medium (¢nal concentration: 50 mM). The
samples were neutralized with NaOH and total cAMP was measured
using a cAMP [125I] scintillation proximity assay following the acetyl-
ation protocol (RPA 542; Amersham, UK).
2.4. Ca2+ measurements
Changes in [Ca2]i were estimated by measurements of Fluo-3 £u-
orescence intensity using an inverted microscope (Zeiss Axiovert 135
TV, Oberkochen, Germany) equipped with a 40U Achrostigmat ob-
jective (1.30 numeric aperture, Zeiss) and an IonOptix £uorescence
imaging system (IonOptix, Milton, MA, USA). Oocytes were used
1^2 h after injection of Fluo-3 potassium salt (Molecular Probes,
Eugene, OR, USA) at a ¢nal concentration of 10^20 WM.
2.5. Data analysis
Results are presented as mean values þ S.E.M. for indicated num-
bers of experiments. Statistical signi¢cance was evaluated using Stu-
dent’s t-test for unpaired observations.
3. Results and discussion
3.1. Expression of GLP-1 receptor in Xenopus oocytes
Fig. 1A shows that GLP-1(7^36)amide (50 nM) produces
an oscillatory inward Cl3 current in Xenopus oocytes injected
with cRNA for the human GLP-1 receptor. On average, GLP-
1(7^36)amide evoked a current response of 162 þ 10 nA fol-
lowing a latency of 65 þ 3 s (n = 54 from eight di¡erent frogs).
Application of 10 nM GLP-1(7^36)amide evoked smaller cur-
rent responses of 20^30 nA in amplitude and 50 nM of the
peptide was therefore used throughout this study. Desensiti-
zation of the GLP-1 receptor is not evident and a second
application of GLP-1(7^36)amide evoked a current of about
the same amplitude as during the ¢rst exposure (Fig. 1A). The
average responses from a series of four experiments were
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Fig. 1. Cloned GLP-1 receptor activates inward Cl3 current in Xenopus oocytes. A: E¡ect of two GLP-1(7^36)amide (50 nM) applications on
Cl3 current in a Xenopus oocyte expressing the cloned human GLP-1 receptor. B: Exendin-(9^39) (10 WM) blocks GLP-1(7^36)amide (50 nM)-
induced Cl3 current but not a second GLP-1(7^36)amide application 4 min following wash-out of the antagonist from the bath. C: No e¡ect
of GLP-1(7^36)amide (50 nM) in non-injected oocytes. In this and the following ¢gures the oocytes were exposed to the compounds during the
time indicated by the horizontal lines. The traces are representative of 4^11 experiments.
Fig. 2. Parallel measurements of inward Cl3 current and [Ca2]i in
an oocyte expressing the cloned human GLP-1 receptor. The change
in [Ca2]i is depicted as an increase in Fluo-3 £uorescence intensity
(top trace) whereas the associated inward Cl3 current is shown in
the lower trace. The traces are representative of four other experi-
ments.
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165 þ 50 nA for the ¢rst GLP-1(7^36)amide application and
193 þ 88 nA for the second stimulation. The action of GLP-
1(7^36)amide is speci¢c since application of GLP-1(7^
36)amide in the presence of the GLP-1 receptor antagonist
exendin-(9^39) (10 WM) abolished the stimulatory e¡ect of
GLP-1(7^36)amide (Fig. 1B). A second application of GLP-
1(7^36)amide 4 min following wash-out of exendin-(9^39)
evoked a current response of 200 nA. No e¡ect of GLP-
1(7^36)amide was observed in non-injected oocytes (n = 11;
Fig. 1C).
3.2. GLP-1 receptor activation causes Ins(1,4,5)P3-dependent
intracellular Ca2+ release
The above data show that GLP-1 receptors are functionally
expressed in Xenopus oocytes and stimulation of these recep-
tors by GLP-1(7^36)amide induces activation of an inward
Cl3 current. It is generally accepted that oocytes are equipped
with Ca2-activated Cl3 channels and we next investigated
whether changes in [Ca2]i couple GLP-1 receptor stimulation
to activation of the Cl3 current. Fig. 2 shows that stimulation
of oocytes expressing the GLP-1 receptor with 50 nM GLP-
1(7^36)amide results in a pronounced increase in Fluo-3 £uo-
rescence intensity re£ecting an elevation of [Ca2]i which was
associated with induction of an inward Cl3 current. In all
tested oocytes the rise in [Ca2]i was transient and with no
oscillations (n = 5). The oscillatory nature of the Cl3 current
observed in many oocytes is likely to re£ect local changes in
[Ca2]i, whereas the £uorescence measurements report average
[Ca2]i in the oocyte. This is in keeping with previous obser-
vations that the membrane current responses do not simply
mirror the Ca2 signals [7].
To further substantiate the Ca2 dependence of the Cl3
current oocytes were injected with the Ca2 chelator BAPTA
(¢nal concentration 100 WM). In BAPTA-loaded oocytes the
stimulatory action of GLP-1(7^36)amide was abolished
whereas control injected oocytes responded to an application
of this hormone (Fig. 3A,B). On average, BAPTA completely
blocked the GLP-1(7^36)amide-evoked current response (n=4)
whereas control injected oocytes produced an average current
of 188 þ 16 nA (n = 5). Injection of the Ins(1,4,5)P3 receptor
antagonist heparin (¢nal concentration 100 Wg/ml) into oo-
cytes expressing the GLP-1 receptor strongly reduced the
GLP-1(7^36)amide-evoked current (Fig. 3C,D). In this series
of experiments, we observed a 97% (P6 0.025) block of the
Cl3 currents from 252 þ 70 nA in control (n = 6) to 18 þ 14 nA
(n = 4) in heparin-injected oocytes. In contrast (Fig. 3E), pre-
treating oocytes for s 30 min with 50 WM ryanodine, an in-
hibitor of the process of Ca2-induced Ca2 release, had no
e¡ect on the ability of GLP-1(7^36)amide to evoke a current
response: 105 þ 6 nA in ryanodine-treated oocytes (n = 5) vs.
124 þ 31 nA in control (n = 3). Similar negative results were
observed following injection of oocytes with ryanodine (¢nal
concentrations: 50^200 WM) s 1 h prior to the experiments.
3.3. GLP-1(7^36)amide activates Ca2+-dependent Cl3 current
independently of the adenylate cyclase/PKA system
Measurements of cAMP levels revealed that the cloned hu-
man GLP-1 receptor associates with endogenous adenylate
FEBS 20015 27-3-98
Fig. 3. Activation of GLP-1 receptor evokes Ins(1,4,5)P3-dependent intracellular Ca2 mobilization. A: Lack of e¡ect of GLP-1(7^36)amide in
oocytes injected s 0.5 h prior to the experiments with BAPTA (¢nal concentration 100 mM) but not in control injected oocytes (B). C: Micro-
injection of the inositol trisphosphate receptor antagonist heparin (100 Wg/ml) strongly reduced response to GLP-1(7^36)amide (50 nM) stimula-
tion but not in control oocytes (D). E: Current response obtained from oocytes pretreated for s 0.5 h with 100 WM ryanodine. The traces are
representative of 4^6 experiments.
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cyclase in the oocytes since cAMP formation was increased
s 7-fold from 20 þ 2 nM to 168 þ 24 nM (P6 0.001; n = 4)
following a 15 min GLP-1(7^36)amide (50 nM) stimulation.
Fig. 4A shows that application of the adenylate cyclase acti-
vator forskolin (10 WM) does not mimic the stimulatory e¡ect
of GLP-1(7^36)amide. Furthermore, neither the latency nor
the amplitude of the Cl3 current evoked in response to sub-
sequent GLP-1(7^36)amide stimulation was a¡ected (Fig.
4A,B). However, the lack of e¡ect of forskolin on the Cl3
conductance does not re£ect its inability to stimulate cAMP
production which increased s 2.5-fold following a 15 min
stimulation. The ability of GLP-1(7^36)amide to stimulate
Ca2-dependent Cl3 currents does not involve activation of
PKA as indicated by the observation that intracellular injec-
tion of the speci¢c PKA inhibitor Rp-cAMPS (¢nal concen-
tration 50 WM [8]) did not interfere with the stimulatory ac-
tion of GLP-1(7^36)amide (Fig. 4B).
It is generally accepted that the e¡ect of GLP-1(7^36)amide
is mediated by the G-protein subunit GsK [9]. However, this is
most likely not the case in Xenopus oocytes since pretreatment
for s 20 h with 100 ng/ml cholera toxin or pertussis toxin did
not a¡ect the amplitude of the GLP-1(7^36)amide-evoked Cl3
current (Fig. 4B). These results suggest that the GLP-1 recep-
tor-evoked intracellular Ca2 mobilization occurs independ-
ently of cAMP and activation of PKA.
3.4. Conclusions
Activation of the human GLP-1 receptor expressed in Xe-
nopus oocytes results in Ins(1,4,5)P3-mediated intracellular
Ca2 mobilization and activation of Ca2-dependent Cl3 cur-
rents. The latency of the GLP-1(7^36)amide-evoked current
results mainly from rate-limiting steps in the signal transduc-
tion pathway between receptor binding and Ins(1,4,5)P3 lib-
eration but may also to a lesser extent be a consequence of a
slowly rising level of Ins(1,4,5)P3 towards a threshold required
before Ca2 release is triggered [10]. More importantly, the
signal transduction pathway utilized by the GLP-1 receptor in
oocytes is independent of the cAMP/PKA signaling system
despite an observed GLP-1- (and forskolin-) stimulated in-
crease in cAMP formation. This contrasts with previous re-
ports on GLP-1 receptor signaling via [Ca2]i which is de-
pendent on the receptor’s ability to generate cAMP [3^5,11].
In one study it was demonstrated that the GLP-1 receptor
coupled not only to adenylate cyclase but also to PLC follow-
ing transient expression in a monkey kidney cell line [2]. Cou-
pling to both the adenylate cyclase and PLC signaling systems
has also been observed for the structurally related glucagon
receptor [12]. Interestingly, activation of the PACAP-3 recep-
tor expressed in Xenopus oocytes by both VIP and PACAP
elicits Ca2-activated Cl3 currents suggesting that PACAP-3
receptors may also couple to PLC [13]. Some splice variants of
the PACAP-2 receptor also couple to PLC [14]. This demon-
strates that the cellular signaling mechanism delineated in the
present study for the GLP-1 receptor may be operational for a
larger group of membrane receptors in the glucagon-secretin
family that all signal via increased cAMP formation and
changes in [Ca2]i.
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Fig. 4. Stimulatory e¡ect of GLP-1(7^36)amide on Ca2-activated
Cl3 currents does not involve the cAMP/PKA signaling system. A:
Consecutive applications of forskolin (10 WM) and GLP-1(7^
36)amide (50 nM) to oocytes expressing the cloned human GLP-1
receptor. B: Histograms showing average e¡ects of GLP-1(7^
36)amide on Ca2-activated Cl3 currents in oocytes exposed to for-
skolin (10 WM) for 3 min; pertussis toxin (PTX) or cholera toxin
(CTX) 100 ng/ml for s 20 h; or microinjected with the PKA inhibi-
tor Rp-cAMPS (50 WM) for s 0.5 h prior to the experiments. Mean
values þ S.E.M. of 3^8 experiments in each series.
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